Claims
- 1. An aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.
- 2. The aerosol suspension formulation of claim 1, comprising about 1 to about 5 weight percent ethanol.
- 3. The aerosol suspension formulation of claim 1, comprising about 2 to about 5 weight percent ethanol.
- 4. The aerosol suspension formulation of claim 1, which contains a surfactant.
- 5. The aerosol suspension formulation of claim 4, wherein the surfactant comprises oleic acid.
- 6. The aerosol suspension formulation of claim 1, which is contained in a metered dose container.
- 7. The aerosol suspension formulation of claim 1, which is contained in apparatus delivering a measured amount of about 10 to about 500 micrograms of mometasone furoate from a single actuating operation.
- 8. A method for treating allergic reactions in the respiratory tract, comprising administering by inhalation an aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.
- 9. The method of claim 8, wherein the suspension comprises about 1 to about 5 weight percent ethanol.
- 10. The method of claim 8, wherein the suspension comprises about 2 to about 5 weight percent ethanol.
- 11. The method of claim 8, wherein the suspension contains a surfactant.
- 12. The method of claim 11, wherein the surfactant comprises oleic acid.
- 13. The method of claim 8, wherein the suspension is contained in a metered dose container.
- 14. The method of claim 8, wherein the suspension is contained in apparatus delivering a measured amount of about 10 to about 500 micrograms of mometasone furoate from a single actuating operation.
- 15. A metered dose inhaler which contains an aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.
- 16. The metered dose inhaler of claim 15, wherein about 10 to about 500 micrograms of mometasone furoate are delivered from a single actuating operation.
- 17. The metered dose inhaler of claim 15, which is adapted for nasal delivery of mometasone furoate.
- 18. The metered dose inhaler of claim 15, which is adapted for lower airway delivery of mometasone furoate.
Parent Case Info
This application claims benefit of provisional application Ser. No. 60/025,807 filed Aug. 29, 1996.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
5118494 |
Schultz et al. |
Jun 1992 |
|
5225183 |
Purewal et al. |
Jul 1993 |
|
5474759 |
Fassberg et al. |
Dec 1995 |
|
5653962 |
Akehurst et al. |
Aug 1997 |
|
5658549 |
Akehurst et al. |
Aug 1997 |
|
5674471 |
Akehurst et al. |
Oct 1997 |
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 656 205 |
Jun 1995 |
EPX |
9206675 |
Apr 1992 |
WOX |
9311745 |
Jun 1993 |
WOX |
9403153 |
Feb 1994 |
WOX |
9520393 |
Aug 1995 |
WOX |